NASDAQ:VTVT vTv Therapeutics (VTVT) Stock Forecast, Price & News $0.79 -0.02 (-2.47%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$0.77▼$0.8150-Day Range$0.72▼$0.9552-Week Range$0.50▼$1.40Volume60,620 shsAverage Volume129,876 shsMarket Capitalization$82.62 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media vTv Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside406.3% Upside$4.00 Price TargetShort InterestBearish4.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.39 out of 5 starsMedical Sector896th out of 1,006 stocksPharmaceutical Preparations Industry446th out of 492 stocks 3.5 Analyst's Opinion Consensus RatingvTv Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, vTv Therapeutics has a forecasted upside of 406.3% from its current price of $0.79.Amount of Analyst CoveragevTv Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.23% of the float of vTv Therapeutics has been sold short.Short Interest Ratio / Days to CovervTv Therapeutics has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.Change versus previous monthShort interest in vTv Therapeutics has recently decreased by 1.69%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldvTv Therapeutics does not currently pay a dividend.Dividend GrowthvTv Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VTVT. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for vTv Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for VTVT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added vTv Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, vTv Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.80% of the stock of vTv Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 8.50% of the stock of vTv Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of vTv Therapeutics is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of vTv Therapeutics is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About vTv Therapeutics (NASDAQ:VTVT) StockvTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.Read More Receive VTVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VTVT Stock News HeadlinesMay 28, 2023 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Receives New Coverage from Analysts at StockNews.comMay 24, 2023 | finance.yahoo.comvTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex PharmaceuticalsJune 1, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.May 21, 2023 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.comMay 17, 2023 | americanbankingnews.comBrokers Offer Predictions for vTv Therapeutics Inc.'s FY2023 Earnings (NASDAQ:VTVT)May 12, 2023 | finanznachrichten.devTv Therapeutics Inc.: vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate UpdateMay 12, 2023 | finance.yahoo.comvTv Therapeutics Insider Ups Holding During YearMay 12, 2023 | finance.yahoo.comvTv Therapeutics Insider Ups Holding During Year \June 1, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.May 12, 2023 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Earns Hold Rating from Analysts at StockNews.comMay 11, 2023 | finance.yahoo.comvTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate UpdateMay 4, 2023 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Now Covered by Analysts at StockNews.comApril 28, 2023 | morningstar.comvTv Therapeutics Inc Class AApril 26, 2023 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Coverage Initiated by Analysts at StockNews.comApril 20, 2023 | finance.yahoo.comCantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19April 18, 2023 | msn.comPromising Upsides on these Biotech Penny StocksApril 11, 2023 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.comMarch 25, 2023 | finance.yahoo.com3 Pharma Stocks That Could Benefit from Global Healthcare TrendsMarch 6, 2023 | finance.yahoo.comvTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateMarch 6, 2023 | finance.yahoo.comCantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain MetastasesMarch 3, 2023 | finance.yahoo.comvTv Therapeutics (NASDAQ:VTVT) investors are sitting on a loss of 88% if they invested five years agoFebruary 27, 2023 | finance.yahoo.comCantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated GlioblastomaFebruary 1, 2023 | finance.yahoo.comElizabeth Keiley Selected as Executive Vice President and General Counsel of vTv TherapeuticsJanuary 31, 2023 | reuters.comVTVT.PH - | Stock Price & Latest News | ReutersJanuary 20, 2023 | finance.yahoo.comPrivate equity firms in vTv Therapeutics Inc. (NASDAQ:VTVT) are its biggest bettors, and their bets paid off as stock gained 21% last weekJanuary 12, 2023 | bizjournals.comvTv Therapeutics names biotechnology industry veteran Steven Tuch as CFOJanuary 9, 2023 | finance.yahoo.comCANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMASee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VTVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VTVT Company Calendar Last Earnings5/11/2023Today6/01/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VTVT CUSIPN/A CIK1641489 Webwww.vtvtherapeutics.com Phone(336) 841-0300Fax336-841-0310Employees9Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+406.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,160,000.00 Net MarginsN/A Pretax Margin-119,016.66% Return on EquityN/A Return on Assets-49.51% Debt Debt-to-Equity RatioN/A Current Ratio2.42 Quick Ratio2.42 Sales & Book Value Annual Sales$2.02 million Price / Sales40.90 Cash FlowN/A Price / Cash FlowN/A Book Value($0.18) per share Price / Book-4.39Miscellaneous Outstanding Shares104,580,000Free Float103,740,000Market Cap$82.62 million OptionableNot Optionable Beta-1.20 Key ExecutivesPaul Jai SekhriPresident, Chief Executive Officer & DirectorSteven TuchChief Financial OfficerCarmen ValcarceChief Scientific Officer & Executive VPElizabeth M. KeileyExecutive Vice President & General CounselVanessa McDadeChief Administration OfficerKey CompetitorsXilio TherapeuticsNASDAQ:XLOInterCureNASDAQ:INCRTiziana Life SciencesNASDAQ:TLSAEliem TherapeuticsNASDAQ:ELYMDaré BioscienceNASDAQ:DAREView All CompetitorsInsidersJohn A FryBought 20,539 shares on 11/28/2022Total: $17,047.37 ($0.83/share)View All Insider Transactions VTVT Stock - Frequently Asked Questions Should I buy or sell vTv Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VTVT shares. View VTVT analyst ratings or view top-rated stocks. What is vTv Therapeutics' stock price forecast for 2023? 3 Wall Street analysts have issued twelve-month price targets for vTv Therapeutics' stock. Their VTVT share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 406.3% from the stock's current price. View analysts price targets for VTVT or view top-rated stocks among Wall Street analysts. How have VTVT shares performed in 2023? vTv Therapeutics' stock was trading at $0.6628 at the beginning of the year. Since then, VTVT shares have increased by 19.2% and is now trading at $0.79. View the best growth stocks for 2023 here. When is vTv Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our VTVT earnings forecast. How were vTv Therapeutics' earnings last quarter? vTv Therapeutics Inc. (NASDAQ:VTVT) issued its earnings results on Thursday, May, 11th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. What other stocks do shareholders of vTv Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA). When did vTv Therapeutics IPO? (VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers. What is vTv Therapeutics' stock symbol? vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT." How do I buy shares of vTv Therapeutics? Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is vTv Therapeutics' stock price today? One share of VTVT stock can currently be purchased for approximately $0.79. How much money does vTv Therapeutics make? vTv Therapeutics (NASDAQ:VTVT) has a market capitalization of $82.62 million and generates $2.02 million in revenue each year. The biotechnology company earns $-19,160,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. How can I contact vTv Therapeutics? vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The official website for the company is www.vtvtherapeutics.com. The biotechnology company can be reached via phone at (336) 841-0300, via email at ir@vtvtherapeutics.com, or via fax at 336-841-0310. This page (NASDAQ:VTVT) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.